• Japanese
  • Korean
  • Chinese
Cover Image

Bacterial Partnering Terms and Agreements

The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in bacterial partnering deals

Average deal terms for headline, upfront and royalty by stage of development

Bacterial partnering agreement structure

Bacterial partnering contract documents

Top bacterial deals by value

Most active bacterial dealmakers

Description

The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter bacterial partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bacterial technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual bacterial deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of bacterial dealmaking and business activities.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in bacterial dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading bacterial deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of bacterial deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all bacterial deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all bacterial partnering deals signed and announced since 2009. The chapter is organized by specific infectives therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all bacterial partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in bacterial partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bacterial technologies and products.

Report scope

Bacterial Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to bacterial trends and structure of deals entered into by leading companies worldwide.

Bacterial Partnering Terms and Agreements includes:

  • Trends in bacterial dealmaking in the biopharma industry since 2009
  • Analysis of bacterial deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of bacterial deal contract documents
  • Comprehensive access to over 1,000 bacterial deal records
  • The leading bacterial deals by value since 2009
  • Most active bacterial dealmakers since 2009

In Bacterial Partnering Terms and Agreements, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Bacterial Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,000 bacterial deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise bacterial rights granted or optioned
  • What is actually granted by the agreement to the partner company
  • What exclusivity is granted
  • What is the payment structure for the deal
  • How aresalesand payments audited
  • What is the deal term
  • How are the key terms of the agreement defined
  • How are IPRs handled and owned
  • Who is responsible for commercialization
  • Who is responsible for development, supply, and manufacture
  • How is confidentiality and publication managed
  • How are disputes to be resolved
  • Under what conditions can the deal be terminated
  • What happens when there is a change of ownership
  • What sublicensing and subcontracting provisions have been agreed
  • Which boilerplate clauses does the company insist upon
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type
  • Which jurisdiction does the company insist upon for agreement law

Benefits

Bacterial Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of bacterial deal trends since 2009
  • Access bacterial deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between bacterial partner companies
  • Comprehensive access to over 1,000 links to actual bacterial deals entered into by the world's biopharma companies
  • Indepth review of bacterial deals entered into by the leading fifty bigpharma companies
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner bacterial opportunities
  • Uncover companies actively partnering bacterial opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in bacterial dealmaking

  • 2.1. Introduction
  • 2.2. Bacterial partnering over the years
  • 2.3. Big pharma bacterial dealmaking activity
  • 2.4. Big biotech bacterial dealmaking activity
  • 2.5. Most active in bacterial partnering
  • 2.6. Bacterial partnering by deal type
  • 2.7. Bacterial partnering by industry sector
  • 2.8. Bacterial partnering by stage of development
  • 2.9. Bacterial partnering by technology type
  • 2.10. Bacterial partnering by bacterial indication
  • 2.11. Average deal terms for bacterial
    • 2.11.1 Bacterial headline values
    • 2.11.2 Bacterial upfront payments
    • 2.11.3 Bacterial milestone payments
    • 2.11.4 Bacterial royalty rates

Chapter 3 - Leading bacterial deals

  • 3.1. Introduction
  • 3.2. Top bacterial deals by value

Chapter 4 - Big pharma bacterial deals

  • 4.1. Introduction
  • 4.2. How to use big pharma partnering deals
  • 4.3. Big pharma bacterial partnering company profiles
  • Abbott
  • Actavis
  • Allergan
  • Amgen
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • CSL
  • Daiichi Sankyo
  • Dainippon Sumitomo
  • Eisai
  • Eli Lilly
  • Endo Pharmaceuticals
  • Forest Laboratories
  • Fresenius
  • Galderma
  • Gilead Sciences
  • GlaxoSmithKline
  • Grifols
  • Hospira
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Lundbeck
  • Menarini
  • Merck & Co
  • Merck KGaA
  • Mitsubishi Tanabe
  • Mylan
  • Novartis
  • Novo Nordisk
  • Otsuka
  • Pfizer
  • Purdue
  • Ranbaxy Laboratories
  • Roche
  • Sanofi
  • Servier
  • Shionogi
  • Shire
  • Stada
  • Takeda
  • Teva
  • UCB
  • Valeant
  • Warner Chilcott

Chapter 5 - Big biotech bacterial deals

  • 5.1. Introduction
  • 5.2. How to use big biotech partnering deals
  • 5.3. Big biotech bacterial partnering company profiles
  • 3SBio
  • Acorda Therapeutics
  • Actelion
  • Alexion Pharmaceuticals
  • Alkermes
  • AMAG Pharmaceuticals
  • Amgen
  • Anika Therapeutics
  • Array Biopharma
  • Bavarian Nordic
  • Biocon
  • Biogen Idec
  • BioMarin Pharmaceuticals
  • Cangene
  • Celgene
  • CSL
  • Cubist
  • Dendreon
  • Elan
  • Emergent BioSolutions
  • Enzo Biochem
  • Galapagos
  • Genmab
  • Gilead Sciences
  • Grifols
  • Ipsen
  • Isis Pharmaceuticals
  • LFB Group
  • Medivation
  • Morphosys
  • Nektar Therapeutics
  • Novo Nordisk
  • NPS Pharmaceuticals
  • Onyx Pharmaceuticals
  • Optimer
  • PDL BioPharma
  • Questcor Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Roche
  • SciClone Pharmaceuticals
  • Seattle Genetics
  • Shire
  • Spectrum Pharmaceuticals
  • Swedish Orphan Biovitrum
  • The Medicines Company
  • UCB
  • United Therapeutics
  • Vertex Pharmaceuticals
  • ViroPharma
  • Zeltia

Chapter 6 - Bacterial partnering contracts directory

  • 6.1. Introduction
  • 6.2. Bacterial partnering by company A-Z
  • 6.3. Bacterial partnering by deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Contract service
  • Co-promotion
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Joint venture
  • Licensing
  • Litigation
  • Loan
  • Manufacturing
  • Manufacturing - OEM
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Termination
  • Warranty
  • 6.4. Bacterial partnering by stage of development
  • 6.5. Bacterial partnering by technology type

Chapter 7 - Bacterial dealmaking by therapeutic target

  • 7.1. Introduction
  • 7.2. Deals by therapeutic target

Appendices

  • Appendix 1 - Directory of bacterial deals by company A-Z 2009-2014
  • Appendix 2 - Directory of bacterial deals by deal type 2009-2014
  • Appendix 3 - Directory of bacterial deals by stage of development 2009-2014
  • Appendix 4 - Directory of bacterial deals by technology type 2009-2014
  • Appendix 5 - Partnering resource center
  • Online partnering
  • Partnering events
  • Further reading on dealmaking
  • Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering
  • Order Form - Therapy Reports
  • Table of figures
  • Figure 1: Bacterial partnering since 2009
  • Figure 2: Big pharma - top 50 - bacterial deals 2009 to 2014
  • Figure 3: Big pharma bacterial deal frequency - 2009 to 2014
  • Figure 4: Big biotech - top 50 - bacterial deals 2009 to 2014
  • Figure 5: Big biotech bacterial deal frequency - 2009 to 2014
  • Figure 6: Active bacterial dealmaking activity- 2009 to 2014
  • Figure 7: Bacterial partnering by deal type since 2009
  • Figure 8: Bacterial partnering by industry sector since 2009
  • Figure 9: Bacterial partnering by stage of development since 2009
  • Figure 10: Bacterial partnering by technology type since 2009
  • Figure 11: Bacterial partnering by [] target since 2009
  • Figure 12: Bacterial deals with a headline value
  • Figure 13: Bacterial deal headline value distribution, US$million - discovery stage
  • Figure 14: Bacterial deal headline value distribution, US$million - preclinical stage
  • Figure 15: Bacterial deal headline value distribution, US$million - phase I stage
  • Figure 16: Bacterial deal headline value distribution, US$million - phase II stage
  • Figure 17: Bacterial deal headline value distribution, US$million - phase III stage
  • Figure 18: Bacterial deal headline value distribution, US$million - regulatory stage
  • Figure 19: Bacterial deal headline value distribution, US$million - marketed stage
  • Figure 20: Summary median headline value by stage of development, 2009-2014
  • Figure 21 Bacterial deals with upfront payment values
  • Figure 22: Bacterial deal upfront payment distribution, US$million - discovery stage
  • Figure 23: Bacterial deal upfront payment distribution, US$million - preclinical stage
  • Figure 24: Bacterial deal upfront payment distribution, US$million - phase I stage
  • Figure 25: Bacterial deal upfront payment distribution, US$million - phase II stage
  • Figure 26: Bacterial deal upfront payment distribution, US$million - phase III stage
  • Figure 27: Bacterial deal upfront payment distribution, US$million - regulatory stage
  • Figure 28: Bacterial deal upfront payment distribution, US$million - marketed stage
  • Figure 29: Summary median upfront payments by stage of development, 2009-2014
  • Figure 30: Bacterial deals with milestone payments
  • Figure 31: Bacterial deal milestone distribution, US$million - discovery stage
  • Figure 32: Bacterial deal milestone distribution, US$million - preclinical stage
  • Figure 33: Bacterial deal milestone distribution, US$million - phase I stage
  • Figure 34: Bacterial deal milestone distribution, US$million - phase II stage
  • Figure 35: Bacterial deal milestone distribution, US$million - phase III stage
  • Figure 36: Bacterial deal milestone distribution, US$million - regulatory stage
  • Figure 37: Bacterial deal milestone distribution, US$million - marketed stage
  • Figure 38: Bacterial deals with royalty rates, %
  • Figure 39: Bacterial deal royalty rate distribution, US$million - discovery stage
  • Figure 40: Bacterial deal royalty rate distribution, US$million - preclinical stage
  • Figure 41: Bacterial deal royalty rate distribution, US$million - phase I stage
  • Figure 42: Bacterial deal royalty rate distribution, US$million - phase II stage
  • Figure 43: Bacterial deal royalty rate distribution, US$million - phase III stage
  • Figure 44: Bacterial deal royalty rate distribution, US$million - regulatory stage
  • Figure 45: Bacterial deal royalty rate distribution, US$million - marketed stage
  • Figure 46: Summary median royalty rate by stage of development, 2009-2014
  • Figure 47: Top bacterial deals by value since 2009
  • Figure 48: Online partnering resources
  • Figure 49: Forthcoming partnering events
Show More
Pricing